No Data
No Data
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $16
Optimistic Buy Rating for Tenaya Therapeutics as Clinical Milestone Nears in Gene Therapy for Cardiomyopathy
Morgan Stanley Initiates Tenaya Therapeutics(TNYA.US) With Buy Rating, Announces Target Price $15
Owning 43% Shares,institutional Owners Seem Interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA),
Tenaya Therapeutics Announces Board Restructuring and New Equity Plan
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
No Data
No Data